Notice: Function _load_textdomain_just_in_time was called incorrectly. Translation loading for the wordpress-seo domain was triggered too early. This is usually an indicator for some code in the plugin or theme running too early. Translations should be loaded at the init action or later. Please see Debugging in WordPress for more information. (This message was added in version 6.7.0.) in /var/www/html/wp-includes/functions.php on line 6260 Array BioPharma Names Jason Haddock CFO | Contract Pharma

What are you searching for?

Sign in
Promotions & Moves

Array BioPharma Names Jason Haddock CFO

Mr. Haddock has more than 15 years of financial and operational experience in the biopharmaceutical industry

Author Image

By: Tim Wright

Editor-in-Chief, Contract Pharma

Array BioPharma, a biopharmaceutical company focused on the discovery, development and commercialization of targeted small molecule drugs to treat patients afflicted with cancer, announced it has appointed Jason Haddock as chief financial officer. Mr. Haddock replaces David Horin, who had been acting as Array’s interim chief financial officer.

Mr. Haddock has more than 15 years of financial and operational experience in the biopharmaceutical industry. He held leadership positions of increasing responsibility at Bristol-Myers Squibb in a variety of accounting, planning, commercial, analytical and business development capacities over more than 13 years through 2015. Mr. Haddock most recently served as chief financial officer and chief operating officer of BERG Health, an oncology focused research, diagnostics and development company, where he oversaw the implementation of financial and operational processes, procedures and policies to transform and scale the company’s practices as it planned for growth and corporate evolution.

“We are pleased to welcome Jason to Array’s executive team during a pivotal time for our company,” said Ron Squarer, chief executive officer, Array. “He brings strong financial and operational expertise across many therapeutic areas and in commercial, medical and operational functions, and is well-versed on the nuances and challenges in the pharmaceutical landscape. We look forward to having Jason in this role as we continue to plan for commercialization of two wholly-owned drugs in the US.”

Add us as a preferred source on Google

Get the latest Contract Pharma news, insights and analysis in your Google Search and AI experiences.

Add Contract Pharma as a preferred source on Google (opens in a new tab)

Keep Up With Our Content. Subscribe To Contract Pharma Newsletters